The PPAR-γ Agonist Pioglitazone Modulates Proliferation and Migration in HUVEC, HAOSMC and Human Arteriovenous Fistula-Derived Cells

The failure of arteriovenous fistulas (AVFs) following intimal hyperplasia (IH) increases morbidity and mortality rates in patients undergoing hemodialysis for chronic kidney disease. The peroxisome-proliferator associated receptor (PPAR-gamma) may be a therapeutic target in IH regulation. In the present study, we investigated PPAR-gamma expression and tested the effect of pioglitazone, a PPAR-gamma agonist, in different cell types involved in IH. As cell models, we used Human Endothelial Umbilical Vein Cells (HUVEC), Human Aortic Smooth Muscle Cells (HAOSMC), and AVF cells (AVFCs) isolated from (i) normal veins collected at the first AVF establishment (T0), and (ii) failed AVF with IH (T1). PPAR-gamma was downregulated in AVF T1 tissues and cells, in comparison to T0 group. HUVEC, HAOSMC, and AVFC (T0 and T1) proliferation and migration were analyzed after pioglitazone administration, alone or in combination with the PPAR-gamma inhibitor, GW9662. Pioglitazone negatively regulated HUVEC and HAOSMC proliferation and migration. The effect was antagonized by GW9662. These data were confirmed in AVFCs T1, where pioglitazone induced PPAR-gamma expression and downregulated the invasive genes SLUG, MMP-9, and VIMENTIN. In summary, PPAR-gamma modulation may represent a promising strategy to reduce the AVF failure risk by modulating cell proliferation and migration.

Automated summary

The failure of arteriovenous fistulas due to intimal hyperplasia is a serious problem for patients undergoing hemodialysis. This study investigated the role of the PPAR-gamma in regulating intimal hyperplasia and found that the PPAR-gamma agonist pioglitazone had a negative effect on cell proliferation and migration.